使用CardioCel行主动脉瓣重建的中期结果
本研究评估了使用CardioCel补片行主动脉瓣修复的中期结局。2014年9月至2021年6月共167例患者接受主动脉瓣重建,均使用CardioCel补片。早期死亡率为0.6%,6年生存率95.7%,6年再手术和/或主动脉瓣反流≥3+的累积风险为7.8±2.5%。结论认为中期结果良好,修复失败主要与瓣膜解剖病理和瓣叶质量有关,需进一步评估长期耐久性。
要点
- 使用CardioCel补片行主动脉瓣修复的中期结果良好,6年再手术和/或反流≥3+累积风险为7.8±2.5%。
- 修复失败的主要原因为瓣膜解剖病理和瓣叶质量,未观察到CardioCel退变或钙化。
- 需进一步研究评估CardioCel补片作为生物瓣替换替代方案的长期耐久性。
核心结论
- 使用CardioCel行主动脉瓣叶修复的中期结果良好。
- 主动脉瓣解剖病理和瓣叶质量似乎是修复失败的主要原因。
- 需要进一步研究评估CardioCel补片成形术作为特定主动脉瓣病变生物瓣替换替代方案的长期耐久性。
研究设计与样本
- 回顾性研究,2014年9月至2021年6月共167例患者接受主动脉瓣重建并使用CardioCel补片。
- 117例(70%)行孤立瓣叶修复,50例(43%)合并主动脉病变行瓣膜和根部联合修复。
主要发现
- 早期(30天/院内)死亡率为0.6%。
- 2年、4年和6年生存率分别为98.8%、96.8%和95.7%。
- 平均随访4.2±1.7年(共697患者年),10例患者出现相关主动脉瓣反流(其中8例为二叶瓣)。
- 所有反流患者均接受瓣膜替换,6年主动脉瓣再手术和/或反流≥3+的累积风险为7.8±2.5%。
- 再手术原因分别为缝合线处瓣叶撕裂4例、进展性瓣膜病理4例、心内膜炎1例和未知1例;未观察到CardioCel退变和/或钙化。
关键数值与推荐
- 早期(30天/院内)死亡率为0.6%。
- 6年生存率为95.7%。
- 6年主动脉瓣再手术和/或反流≥3+的累积风险为7.8±2.5%。
临床怎么用
- 对于特定主动脉瓣病变,使用CardioCel补片行瓣叶修复可作为生物瓣替换的替代方案,中期结果良好。
- 术前应评估主动脉瓣解剖病理和瓣叶质量,因其与修复失败相关。
局限性
- 需要进一步研究评估CardioCel补片成形术的长期耐久性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of the study was to evaluate the outcomes of aortic valve repair techniques using cusp patch-plasty with CardioCel. METHODS: Between September 2014 and June 2021, a total of 167 patients underwent aortic valve reconstruction using cusp repair. In all patients, CardioCel patch was used exclusively. An isolated cusp repair was performed in 117 patients (70%), while 50 patients with concomitant aortopathy needed a combined valve and root repair. Seventy-two patients (43%) presented with tricuspid valve. The mean age of the entire cohort was 54.3 ± 12.3 years, with 143 patients being males. RESULTS: Early (30-day/in-hospital) mortality was 0.6%. The survival at 2, 4, and 6 years was 98.8, 96.8, and 95.7%, respectively. During the mean follow-up of 4.2 ± 1.7 years (resulting in 697 patient-years), a relevant aortic insufficiency occurred in 10 patients (8 of them presenting with bicuspid valve). All the patients underwent a valve replacement, resulting in a 7.8 ± 2.5% cumulative risk of aortic valve reoperation and/or insufficiency ≥3+ at 6 years. The causes of reoperation were cusp tear at the suture line, progressive valve pathology, endocarditis, and unknown in 4, 4, 1, and 1, respectively. Degeneration and/or calcification of the CardioCel has not been observed. CONCLUSIONS: The intermediate results of aortic cusp repair using CardioCel are good. Anatomo-pathology of the aortic valve and quality of the cusps seem to be the main reasons for repair failure. Further investigations are needed to assess the long-term durability of CardioCel patch-plasty as an alternative to biological valve replacement in specific aortic valve pathologies.
引用
- Irimie VP, Nasra W, Atieh A, et al. Aortic valve reconstruction with CardioCel: Midterm Results. Eur J Cardiothorac Surg. 2025. PMID: 39969987. doi:10.1093/ejcts/ezaf049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。